Home | All trials

[RDF data]
Trial NCT00000152

Resource URI: http://static.linkedct.org/resource/trials/NCT00000152
PropertyValue
linkedct:brief_title Randomized Trial of Beta-Carotene and Macular Degeneration
linkedct:condition <http://static.linkedct.org/resource/condition/7633>
linkedct:criteria When the Physicians Health Study was established in the early 1980s by the NHLBI to collect data on a stable population at risk for heart attack, only male physicians were studied because males were thought to be at higher risk than females for ischemic heart problems. The study population consists of 22,071 male U.S. physicians who were aged 40 to 84 years in 1982. The subjects have no history of myocardial infarction, cancer, kidney disease, renal disease, or any other contraindication to the use of aspirin or beta-carotene, including regular use of corticosteroids.
linkedct:description Macular degeneration, a major cause of blindness in the United States, is the leading cause of new cases of blindness in people aged 65 and older. The National Eye Institute estimates that each year an additional 165,000 people, mainly in the older age groups, develop macular disease. Among all people with macular degeneration, approximately 116,000 are affected by the neovascular form of the disease. Although laser treatment is an effective treatment for patients with certain forms of neovascular membranes (exudative AMD), for most patients there is no available treatment. The pathogenesis of AMD is only partly understood, and its etiology remains obscure. The Retinal and Choroidal Diseases Panel of the National Advisory Eye Council has stated that "none of the fundamental causes of any type of macular disease is known, and none can be prevented." Thus, this panel recommended that one of the NEI's program development priorities should be to "initiate epidemiologic studies of macular diseases to identify possible causative, protective, or aggravating factors." This trial is part of the Physicians Health Study, sponsored by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, with funding for eye epidemiologic data evaluations provided by the NEI. It is an ongoing, randomized, placebo-controlled trial of aspirin in the prevention of cardiovascular mortality and of beta-carotene in the prevention of cancer. Following randomization, each of the 22,071 physicians enrolled was assigned to one of four groups to take either aspirin or its placebo and beta-carotene or its placebo. Followup questionnaires are sent 6 and 12 months after randomization and every 12 months thereafter. The average length of followup is now greater than 12 years. The hypothesis that beta-carotene levels are inversely related to AMD is supported by experimental studies on the relationship between antioxidants and retinal morphology and function. There is increasing evidence that visible and ultraviolet light can damage the retina through production of superoxide radicals. Antioxidants (including beta-carotene, vitamins A, E, and C, and selenium) protect against oxidative damage by acting as scavengers for the superoxide radicals. Epidemiologic data from the first National Health and Nutrition Examination Survey (NHANES-1) are also consistent with a link between antioxidants and AMD; the frequency of consumption of fruits and vegetables rich in vitamin A (beta-carotene) was negatively correlated with AMD after adjustment for demographic and medical factors. Data from this study will determine whether one 50-mg beta-carotene capsule taken on alternate days protects against the development of AMD and whether additional risk factors emerge after simultaneous controlling for other potential confounding factors. Reported diagnoses of AMD are confirmed by medical record review. The primary analysis will be a comparison of incidence of reported AMD in the beta-carotene and placebo groups. The Cox proportional hazards model will also be used to determine whether there is a difference in time to diagnosis of AMD between the two groups.
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Male
linkedct:eligibility_healthy_volunteers Accepts Healthy Volunteers
linkedct:eligibility_maximum_age 84 Years
linkedct:eligibility_minimum_age 40 Years
linkedct:enrollment 0 (xsd:int)
linkedct:firstreceived_date September 23, 1999
linkedct:id NCT00000152
rdfs:label Trial NCT00000152
linkedct:lastchanged_date June 23, 2005
linkedct:lead_sponsor_agency National Eye Institute (NEI)
linkedct:nct_id NCT00000152
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:org_study_id NEI-54
linkedct:overall_status Active, not recruiting
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000152>
linkedct:phase Phase 3
linkedct:reference <http://static.linkedct.org/resource/reference/51030>
linkedct:source National Eye Institute (NEI)
linkedct:start_date April 1982
linkedct:study_design Prevention, Randomized, Placebo Control
linkedct:study_type Interventional
linkedct:summary To determine whether 50 mg of beta-carotene taken every other day reduces the risk of developing age-related macular degeneration (AMD) among male U.S. physicians who were aged 40 to 84 in 1982. To investigate the possible relationship of AMD with other antioxidants, including selenium and vitamins A, C, and E. To identify potential risk factors for development of AMD. Possible risk factors include height, systemic hypertension, cardiovascular disease, blood cholesterol, cigarette smoking, iris and skin color, sunlight exposure, body mass index, diabetes, and alcohol intake.
rdf:type linkedct:trials
linkedct:verification_date September 2001